Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 38 points (0.2%) at 16,236 as of Thursday, Feb. 27, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,761 issues advancing vs. 1,149 declining with 174 unchanged. The Drugs industry currently sits up 0.4% versus the S&P 500, which is up 0.2%. Top gainers within the industry include Jazz Pharmaceuticals ( JAZZ), up 2.7%, Valeant Pharmaceuticals International ( VRX), up 1.6%, Regeneron Pharmaceuticals ( REGN), up 1.2%, Perrigo Company ( PRGO), up 1.2% and Novartis ( NVS), up 1.0%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. Incyte ( INCY) is one of the companies pushing the Drugs industry lower today. As of noon trading, Incyte is down $1.06 (-1.6%) to $66.20 on light volume. Thus far, 607,215 shares of Incyte exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $65.98-$68.27 after having opened the day at $66.96 as compared to the previous trading day's close of $67.26. Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation. Incyte has a market cap of $11.3 billion and is part of the health care sector. Shares are up 32.9% year-to-date as of the close of trading on Wednesday. Currently there are 12 analysts that rate Incyte a buy, 1 analyst rates it a sell, and 1 rates it a hold. TheStreet Ratings rates Incyte as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and deteriorating net income. Get the full Incyte Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.